FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote

After a long day of deliberations, the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee late Wednesday voted against approving BrainStorm Cell Therapeutics’ experimental amyotrophic lateral sclerosis therapy, NurOwn, by a vote of 17-1.